Kezar Life Sciences (KZR) Equity Average (2021 - 2025)
Kezar Life Sciences (KZR) has disclosed Equity Average for 5 consecutive years, with $76.5 million as the latest value for Q4 2025.
- For Q4 2025, Equity Average fell 39.02% year-over-year to $76.5 million; the TTM value through Dec 2025 reached $76.5 million, down 39.02%, while the annual FY2025 figure was $93.5 million, 38.59% down from the prior year.
- Equity Average hit $76.5 million in Q4 2025 for Kezar Life Sciences, down from $87.4 million in the prior quarter.
- Across five years, Equity Average topped out at $290.3 million in Q3 2022 and bottomed at $76.5 million in Q4 2025.
- Average Equity Average over 5 years is $177.4 million, with a median of $159.9 million recorded in 2024.
- Year-over-year, Equity Average skyrocketed 132.81% in 2022 and then plummeted 39.07% in 2025.
- Kezar Life Sciences' Equity Average stood at $158.2 million in 2021, then soared by 74.82% to $276.5 million in 2022, then dropped by 27.03% to $201.8 million in 2023, then crashed by 37.81% to $125.5 million in 2024, then crashed by 39.02% to $76.5 million in 2025.
- According to Business Quant data, Equity Average over the past three periods came in at $76.5 million, $87.4 million, and $97.4 million for Q4 2025, Q3 2025, and Q2 2025 respectively.